Simcere Pharmaceutical
先声药业
Executive Summary
Simcere Pharmaceutical is a Nanjing-based pharma company listed on Hong Kong Stock Exchange with clear BIOSECURE status, making it a viable partner for US deals. The company operates in China's pharmaceutical sector but lacks publicly available detailed pipeline or recent deal activity data. With clear regulatory status and established public listing, Simcere presents moderate BD potential pending deeper pipeline assessment.
Structure: Simcere is structured as a Hong Kong-listed entity (2096.HK) headquartered in Nanjing, likely employing a standard VIE structure common for Chinese companies accessing international capital markets. The corporate structure appears straightforward for a Chinese pharmaceutical company, though specific subsidiary relationships and holding company layers require verification during due diligence.
Ownership & Shareholder Structure
Clinical Trials(50 total)
2
Phase 3
5
Phase 2
10
Phase 1
1
Other
1
Phase 1, Phase 2
1
Phase 4
| NCT ID | Interventions | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT07393451 | SIM0278 injection | Ph.2 | NOT YET RECRUITING | 60 |
| NCT07402512 | SIM0916, SIM0916 Placebo | Ph.3 | NOT YET RECRUITING | 498 |
| NCT07348211 | SIM0610 for Injection, SIM0610 for Injection | Ph.1 | RECRUITING | 260 |
| NCT07345364 | SIM0811, Placebo | Ph.1 | NOT YET RECRUITING | 56 |
| NCT06686745 | SIM0508 Tablets, SIM0508 in combination with olaparib, SIM0508 in combination with olaparib | Ph.1 | RECRUITING | 130 |
| NCT06701149 | Rademikibart injection, CBP-201 injection | Ph.1 | NOT YET RECRUITING | 178 |
| NCT06680921 | SIM0270, Everolimus (Afinitor®), Exemestane tablets, Fulvestrant injection | Ph.3 | RECRUITING | 460 |
| NCT06698965 | Chemotherapy （Etoposide and Carboplatin）, Immunotherapy （Envafolimab）, Trilaciclib | Ph.2 | RECRUITING | 52 |
| NCT06456281 | A noninvasive cfDNA multi-omics assay | RECRUITING | 480 | |
| NCT06315231 | Edaravone dexborneol sublingual tablet, Placebo | Ph.2 | RECRUITING | 226 |
| NCT06778603 | a targeted probe B7H3-IRDye800CW | Ph.1, Ph.2 | RECRUITING | 32 |
| NCT07266493 | Chemotherapy （Albumin bound paclitaxel and Carboplatin） | Ph.2 | RECRUITING | 26 |
| NCT05940883 | Y-2 Sublingual Tablet, Y-2 Sublingual Tablet, Y-2 Sublingual Tablet, Y-2 Sublingual Tablet, Y-2 Sublingual Tablet, Placebo | Ph.1 | COMPLETED | 36 |
| NCT05803135 | Iguratimod combined with Tofacitinib; | Ph.4 | UNKNOWN | 138 |
| NCT05569057 | SIM1811-03 | Ph.1 | UNKNOWN | 100 |
| NCT05533892 | Nocardia rubra cell wall skeleton, Hepatic arterial infusion chemotherapy, Lenvatinib, Tislelizumab | Ph.1 | UNKNOWN | 30 |
| NCT05475834 | SIM0417 | Ph.1 | COMPLETED | 6 |
| NCT05293964 | SIM0270, Palbociclib, everolimus | Ph.1 | ACTIVE NOT RECRUITING | 214 |
| NCT05781386 | SIM1811-03 or in combination with Sintilimab injectiont | Ph.1 | UNKNOWN | 255 |
| NCT05148195 | Envofolimab, BD0801, Docetaxel, Irinotecan, Leucovorin calcium, 5-Fluorouridine | Ph.2 | TERMINATED | 86 |
Showing 20 of 50 trials
BIOSECURE Risk
Company has clear BIOSECURE status and is not designated under BCC categories, indicating minimal regulatory barriers for US partnerships
Key Exposures:
- •Potential future policy changes
- •Supply chain dependencies in China
Mitigation: Currently maintaining clear status with no apparent BIOSECURE mitigation activities required
BD Intelligence
Therapeutic Areas:
Recent Deals: No recent deal activity data available
Approach: Initial outreach to assess pipeline and partnership interest, focusing on therapeutic areas and development stage assets suitable for US market expansion
Red Flags
- ⚠Limited public information availability
- ⚠Lack of recent corporate event visibility
- ⚠Unknown management team and subsidiary structure
Quick Facts
- Key People
- 0
- Subsidiaries
- 0
- CDMO/CRO Subs
- 0
- Genomics Subs
- 0
- Direct BIOSECURE
- 0
- Corp Events
- 0
- Gov-Connected
- 0
- Clinical Trials
- 50
- Publications
- 0
- Drug Molecules
- 0
- Relationships
- 1
Sources & Methodology
Clinical trials data: ClinicalTrials.gov API v2 (50 trials linked to this entity)
SEC BIOSECURE filings: EDGAR EFTS full-text search (850+ filings from 230 companies)
Publications: Europe PMC API (0 publications indexed)
Drug molecules: ChEMBL database (European Bioinformatics Institute)
Financial data: East Money (东方财富) datacenter API / CNINFO (巨潮资讯网)
Corporate structure: Company official filings, HKEX/SSE/SZSE disclosures
Executive profiles: Company official biographies, SEC filings, LinkedIn (where verified)
Data is collected from public sources and updated weekly. Corporate intelligence is verified by a native Mandarin-speaking analyst against Chinese-language primary sources including Tianyancha (天眼查), GSXT (国家企业信用信息公示系统), and CNINFO (巨潮资讯网). This is not financial or legal advice.